As China Hunts For New Cures, Investors Flood U.S. Biotech Firms With Cash


A researcher prepares samples inside a laboratory at BeiGene Ltd.'s research and development center in Beijing, China, on Thursday, May 24, 2018. Chinese investors are putting record amounts of money into U.S.-based biotechnology firms as Beijing seeks to become a powerhouse in developing new medicines, but the investment rush is also fueling concerns that valuations are being pushed to unsustainable levels.



from Biotech News